LABP-69 / AbbVie - LARVOL DELTA

Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases (ECCO-IBD 2024) - "Results NX-13, a novel NLRX1 agonist, resulted in regulation of cellular metabolism: activation of mitochondrial genes such as mt - nd3 & odgh , and concomitant down-regulation of glucose uptake by murine T cells (Fig1A)...LABP-69 also reduced superoxide levels in BMDM...J Immunol 203(12) 3 Tubau-Juni et al. J Immunol 206(Supp)"

Immunology • Inflammation • Inflammatory Bowel Disease • IFNG • NLRC5 • TNFA

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (GlobeNewswire) - "Landos Biopharma, Inc...announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden....NX-13 is currently in a Phase 2 proof-of-concept trial...The Company expects to report topline results in the fourth quarter of 2024."

P1 data • Preclinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis